We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges.
- Authors
Allard, Camille; Cota, Daniela; Quarta, Carmelo
- Abstract
The use of glucagon-like peptide-1 (GLP-1) receptor-based multi-agonists in the treatment of type 2 diabetes and obesity holds great promise for improving glycaemic control and weight management. Unimolecular dual and triple agonists targeting multiple gut hormone-related pathways are currently in clinical trials, with recent evidence supporting their efficacy. However, significant knowledge gaps remain regarding the biological mechanisms and potential adverse effects associated with these multi-target agents. The mechanisms underlying the therapeutic efficacy of GLP-1 receptor-based multi-agonists remain somewhat mysterious, and hidden threats may be associated with the use of gut hormone-based polyagonists. In this review, we provide a critical analysis of the benefits and risks associated with the use of these new drugs in the management of obesity and diabetes, while also exploring new potential applications of GLP-1-based pharmacology beyond the field of metabolic disease.
- Subjects
GLUCAGON-like peptide-1 agonists; METABOLIC disorders; INVESTIGATIONAL drugs; HYPOGLYCEMIC agents; TYPE 2 diabetes; ANTIOBESITY agents; DRUG efficacy; DRUG development; OBESITY; PHARMACODYNAMICS
- Publication
Drugs, 2024, Vol 84, Issue 2, p127
- ISSN
0012-6667
- Publication type
Article
- DOI
10.1007/s40265-023-01982-6